Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Capital Expenditures (2016 - 2025)

Integra Lifesciences Holdings' Capital Expenditures history spans 17 years, with the latest figure at $17.2 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 41.84% year-over-year to $17.2 million; the TTM value through Dec 2025 reached $81.4 million, down 22.01%, while the annual FY2025 figure was $81.4 million, 22.01% down from the prior year.
  • Capital Expenditures for Q4 2025 was $17.2 million at Integra Lifesciences Holdings, up from $15.2 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $29.7 million in Q2 2024 and bottomed at $6.6 million in Q2 2021.
  • The 5-year median for Capital Expenditures is $15.3 million (2024), against an average of $17.2 million.
  • The largest YoY upside for Capital Expenditures was 225.47% in 2021 against a maximum downside of 59.59% in 2021.
  • A 5-year view of Capital Expenditures shows it stood at $27.4 million in 2021, then plummeted by 47.29% to $14.5 million in 2022, then skyrocketed by 69.72% to $24.5 million in 2023, then grew by 20.64% to $29.6 million in 2024, then tumbled by 41.84% to $17.2 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Capital Expenditures are $17.2 million (Q4 2025), $15.2 million (Q3 2025), and $20.1 million (Q2 2025).